apteka.lviDrugs24.com

Monthly offers  -Prices-Offer price Monthly offers 
Latvian pharmacies maps Duty doctors. medicaid
Medicines and generics searching-PricesDrugs search by alphabet
Vaccination offers. Pricelists-Prices-Offer price Vaccination offers
Space Weather Space weather
    
Queues for medical examinationsLists of compensated medicines        E‑health         
 LV 

PIOGLITAZONE TEVA TBL 30MG N28

Attention: Information on this site is provided for informational purposes and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for treating a health problem or disease, or prescribing any medication. iDrugs24.com is not responsible for any damage to your health as the result of self treatment.

# On 2024-Mar-29
PIOGLITAZONE-drug/medicine -tablets aproximate price on "PIOGLITAZONE TEVA TBL 30MG N28 " in Riga city, Latvia is:
  • 19.58€  21.17$  16.74£  2261Rub  225.7SEK  84PLN  77.93₪ 


Maximum allowed state defined price ( from ZVA webpage) Euro:State defined maximum allowed price indicated on the picture on drug/medicine -tablets  PIOGLITAZONE TEVA TBL 30MG N28     Recheck

ATC codeA10BG03 

Active substances: Pioglitazonum

 


Vendor, principal: Teva Pharmaceutical
PIOGLITAZONE TEVA TBL 30MG N28 is compensated medicine in Latvia. 

 Prescription drug (℞) 

Similar or the same name medicines, products list *
Medicament / Item title  Prices Pharmacies chain
PIOGLITAZONE ACCORD 30 MG TABLETĖS N28
8.46€, Mar.2024 Internet pharmacy Lithuania Gintarinė vaistinė nvaistine.lt (Lithuania) Phone: 880010008Buy
PIOGLITAZONE ACCORD 30 MG TABLETĖS N28 (Accord Healthcare)
8.46€, Feb.2024 Internet pharmacy Lithuania 100 metų vaistinė (Lithuania) Phone: +37038159292Buy
PIOGLITAZONE TORRENT 30 MG TABLETĖS N28 (K), Pioglitazonas Rx
12.09€, Dec.2021 Internet pharmacy Lithuania Gintarinė vaistinė nvaistine.lt (Lithuania) Phone: 880010008Buy
PIOGLITAZONE ACCORD 30MG Rx (Accord)
13.29€ , Feb.2024 Internet pharmacy Latvija internetaptieka.lv T. 26699176, Address: Riga, Dzelzavas street 120M, LV-1021. Opening hours: Working days: 9.00-18.00. Prescription medicines can be received in person with a prescription or identity document, or ordered with delivery, if an e-prescription has been issued.Real final price may be varied.
PIOGLITAZONE ACCORD TBL 30MG N28, pioglitasoon Rx
21.56€, Mar.2024 Pharmacy Estonia Aptev.ee, OÜ Mai apteek (Estonia) Phone: 6008844Buy
* This table was compiled fully automatically, independently from any advertisers, transparently and without any modification relaying the open offers available on the mentioned dates.Only the distribution of over-the-counter remedies through the website is permitted in Latvia in accordance with national laws and regulations.

EUROPEAN MEDICINES AGENCY

SCIENCE MEDICINES HEALTH

EMA/222728/2012

EMEA/H/C/002297

EPAR summary for the public

Pioglitazone Teva

pioglitazone

This is a summary of the European public assessment report (EPAR) for Pioglitazone Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pioglitazone Teva.

What is Pioglitazone Teva?

Pioglitazone Teva is a medicine that contains the active substance pioglitazone. It is available as tablets (15, 30 and 45 mg).

Pioglitazone Teva is a generic medicine'. This means that Pioglitazone Teva is similar to a Reference medicine' already authorised in the European Union (EU) called Actos. For more information on generic medicines, see the question-and-answer document here.

What is Pioglitazone Teva used for?

Pioglitazone Teva is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight. It is used in addition to diet and exercise.

Pioglitazone Teva is used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.

Pioglitazone Teva can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable Odual therapy').

Pioglitazone Teva can also be used together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy by mouth (Triple therapy').

An agency of the European Union

WC5EN00125176

7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu

© European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged.

Pioglitazone Teva can also be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.

The medicine can only be obtained with a prescription.

How is Pioglitazone Teva used?

The recommended starting dose of Pioglitazone Teva is 15 or 30 mg once a day. This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed. Pioglitazone Teva should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease). The tablets should be swallowed with water.

Treatment with Pioglitazone Teva should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit. At subsequent reviews prescribers should confirm that benefits to patients are maintained.

How does Pioglitazone Teva work?

Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substance in Pioglitazone Teva, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces. As a consequence, the blood glucose levels are reduced and this helps to control type 2 diabetes.

How has Pioglitazone Teva been studied?

Because Pioglitazone Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the benefits and risks of Pioglitazone Teva?

Because Pioglitazone Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

Why has Pioglitazone Teva been approved?

The CHMP concluded that, in accordance with EU requirements, Pioglitazone Teva has been shown to have comparable quality and to be bioequivalent to Actos. Therefore, the CHMP's view was that, as for Actos, the benefit outweighs the identified risk. The Committee recommended that Pioglitazone Teva be given marketing authorisation.

Other information about Pioglitazone Teva

The European Commission granted a marketing authorisation valid throughout the European Union for Pioglitazone Teva on 26 March 2012.

The full EPAR for Pioglitazone Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. For more information about treatment with Pioglitazone Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

The full EPAR for the reference medicine can also be found on the Agency's website.

Pioglitazone Teva

This summary was last updated in 10-2011.


Pioglitazone Teva


Page 3/3



 Instruction , annotation source: The European Medicines Agency


[*1]

DDD. Information source: WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health


Back


Facebook Tweeter E-mail link
For pharmacies & healthstores For advertisers About

Copyright © 2011-2024 iDrugs24.com. All rights reserved